For research use only. Not for therapeutic Use.
JB170（Cat No.:I045275）is a potent and highly specific PROTAC (proteolysis-targeting chimera) that induces degradation of Aurora-A kinase by linking the Aurora-A inhibitor Alisertib to a Cereblon-binding thalidomide moiety. It degrades Aurora-A with a DC₅₀ of 28 nM and preferentially targets Aurora-A (EC₅₀ = 193 nM) over Aurora-B (EC₅₀ = 1.4 µM). JB170-mediated depletion of Aurora‑A triggers S‑phase cell-cycle arrest by disrupting non‑catalytic functions, leading to apoptosis in cancer cells. This research tool is invaluable for studying both enzymatic and non-enzymatic roles of Aurora-A in cell division and tumor biology.
| CAS Number | 2705844-82-0 |
| Synonyms | 4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-N-[2-[2-[2-[[2-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]oxyacetyl]amino]ethoxy]ethoxy]ethyl]-2-methoxybenzamide |
| Molecular Formula | C48H44ClFN8O11 |
| Purity | ≥95% |
| IUPAC Name | 4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-N-[2-[2-[2-[[2-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]oxyacetyl]amino]ethoxy]ethoxy]ethyl]-2-methoxybenzamide |
| InChI | InChI=1S/C48H44ClFN8O11/c1-65-35-7-4-6-33(50)41(35)43-32-21-27(49)9-11-29(32)42-26(23-53-43)24-54-48(57-42)55-28-10-12-30(37(22-28)66-2)44(61)52-16-18-68-20-19-67-17-15-51-39(60)25-69-36-8-3-5-31-40(36)47(64)58(46(31)63)34-13-14-38(59)56-45(34)62/h3-12,21-22,24,34H,13-20,23,25H2,1-2H3,(H,51,60)(H,52,61)(H,54,55,57)(H,56,59,62) |
| InChIKey | GYKNPXCQINZRLL-UHFFFAOYSA-N |
| SMILES | COC1=C(C(=CC=C1)F)C2=NCC3=CN=C(N=C3C4=C2C=C(C=C4)Cl)NC5=CC(=C(C=C5)C(=O)NCCOCCOCCNC(=O)COC6=CC=CC7=C6C(=O)N(C7=O)C8CCC(=O)NC8=O)OC |
| Chemistry Calculators | Dilution Calculator In vivo Formulation Calculator Molarity Calculator Molecular Weight Calculator Reconstitution Calculator |
